Patent · US Active

Composition and methods for treatment of ornithine transcarbamylase deficiency

US11167043B2 · kind B2 · utility

1Cited by
70References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 20, 2018
Grant dateNov 9, 2021
Priority date
Expiry dateDec 20, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Y201/03003
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.